Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

The trial is powered to show a 15% absolute improvement in MMR over gleevec in newly diagnosed CP patients. As the press release points out the MMR in the tasigna and sprycel trials was 22% and 28%, respectively. Using the average in these two trials of 25%, would require ponatinib to achieve a 40% MMR to meet the primary endpoint. For reference, in the phase 2 trial, ponatinib achieved a 37% MMR in just over 10 months in patients who had already failed at least 2 other tki's. I like our chances, lol.